Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc. (ADIL) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · ADIL · as of Jun 9, 2026
Activity summary
Buy transactions
1
P-Purchase only
Sell transactions
0
12 Months
Buy/Sell ratio
∞
Buy/Sell (by trades)
Overall sentiment
Adial Pharmaceuticals, Inc. insiders have been net buyers of shares over the past 12 Months, which may signal confidence in the company's outlook.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 9, 2026
ADIL insider buying and selling by quarter
ADIL insider selling · ADIL insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 9, 2026
Active insiders
Most active in past 12 months · ADIL ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
ADIL executive sell shares · ADIL board member insider trading · ADIL insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Apr 7, 2026 | Goodman Tony COO · Director | Award | 26,510 | — | Form 4 |
| Apr 7, 2026 | Schuyler Kevin Director | Award | 9,185 | — | Form 4 |
| Apr 7, 2026 | Shah Vinay CFO | Award | 17,325 | — | Form 4 |
| Apr 7, 2026 | Gilliland Robertson H. Director | Award | 9,185 | — | Form 4 |
| Apr 7, 2026 | Claiborne Cary J CEO · Director | Award | 37,985 | — | Form 4 |
| Sep 29, 2023 | Schuyler Kevin Director | Purchase | 700 | $2K | Form 4 |
| May 23, 2023 | Truluck Joseph CFO | Award | 157,500 | — | Form 4 |
| May 23, 2023 | Stilley William B. III Director | Award | 240,800 | — | Form 4 |
| May 23, 2023 | Claiborne Cary J CEO · Director | Award | 420,000 | — | Form 4 |
| Dec 30, 2022 | Stilley William B. III Director | Other | 166,667 | — | Form 4 |
| Sep 20, 2022 | Claiborne Cary J CEO · Director | Award | 75,000 | $32K | Form 4 |
| Sep 19, 2022 | Claiborne Cary J CEO · Director | Award | 25,000 | $11K | Form 4 |
| Aug 18, 2022 | Claiborne Cary J CEO | Award | 1,000,000 | — | Form 4 |
| Feb 23, 2022 | Stilley William B. III CEO · Director | Award | 250,000 | — | Form 4 |
| Dec 30, 2021 | Newman James W. Jr. Director | Purchase | 5,000 | $14K | Form 4 |
| Dec 30, 2021 | Newman James W. Jr. Director | Purchase | 10,000 | $27K | Form 4 |
| Dec 30, 2021 | Newman James W. Jr. Director | Purchase | 10,000 | $27K | Form 4 |
| Dec 23, 2021 | Schuyler Kevin Director | Gift | 312,990 | — | Form 4 |
| Nov 30, 2021 | Stilley William B. III CEO · Director | Purchase | 10,600 | $29K | Form 4 |
| Nov 29, 2021 | Stilley William B. III CEO · Director | Purchase | 10,000 | $26K | Form 4 |
| Nov 26, 2021 | Newman James W. Jr. Director | Purchase | 10,000 | $29K | Form 4 |
| Oct 4, 2021 | Johnson Bankole A. Chief Medical Officer | Sale | 200,000 | $40.00B⚡ | Form 4 |
| Apr 6, 2021 | Johnson Bankole A. Chief Medical Officer | Sale | 150,000 | $375K | Form 4 |
| Jan 26, 2021 | Stilley William B. III CEO · Director | Award | 201,109 | — | Form 4 |
| Jan 26, 2021 | Newman James W. Jr. Director | Award | 2,544 | — | Form 4 |
Stilley William B. III
CEO · Director
Date
Nov 30
Shares
10,600
Price
$2.75
Value
$29K
Stilley William B. III
CEO · Director
Date
Nov 29
Shares
10,000
Price
$2.59
Value
$26K
Johnson Bankole A.
Chief Medical Officer
Date
Oct 4
Shares
200,000
Price
$200000.00
Value
$40.00B ⚡
Johnson Bankole A.
Chief Medical Officer
Date
Apr 6
Shares
150,000
Price
$2.50
Value
$375K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About ADIL insider trading
ADIL insider trades
Adial Pharmaceuticals, Inc. (ADIL) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Goodman Tony (COO · Director), Schuyler Kevin (Director), Shah Vinay (CFO). Over the past 12 months, 5 insiders have filed transactions with the SEC. ADIL insiders have been primarily buying, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Adial Pharmaceuticals, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
ADIL insider trading · 5 questionsThe insiders of Adial Pharmaceuticals, Inc. (ADIL) include executives and directors such as Goodman Tony (COO · Director), Schuyler Kevin (Director), Shah Vinay (CFO), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026